Superparamagnetic PLGA-iron oxide microcapsules for dual-modality US/MR imaging and high intensity focused US breast cancer ablation

Sun, Yong; Zheng, Yuanyi; Ran, Haitao; Zhou, Yang; Shen, Hongxia; Chen, Yu; Chen, Hangrong; Krupka, Tianyi M.; Li, Ao; Li, Pan; Wang, Zhibiao; Wang, Zhigang

doi:10.1016/j.biomaterials.2012.04.062

Cited by 181 publications

(139 citation statements)

References 33 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…The T B was determined to be 65 K. Notably, the blocking temperature value corroborated well with the reported literature of superparamagnetic iron oxide nanoparticles [36,37]. Such superparamagnetic property has been shown critical to the success application of magnetic nanocapsules in areas such as T 2 -weighted magnetic ressonance imaging, drug delivery and magneto-hyperthermia [38]. For study the efficiency of the entrapment of maghemite nanoparticles in PCL nanocapsules, we compared the surface properties of empty PCL nanocapsules with optimized MagPCL-NC and pure maghemite.…”

supporting

confidence: 85%

Superparamagnetic maghemite loaded poly (ε- caprolactone) nanocapsules : characterization and synthesis optimization

et al. 2014

View full text Add to dashboard Cite

Iron oxide nanoparticles (ION) have been studied for essential applications, like detection of biological constituents (virus, bacterials, cell, nucleic acids, protein, enzyme, etc.), magnetic bioseparation and clinic therapy and diagnosis (such as MRI magnetic fluid and hyperthermia). In this work, γ-Fe 2 O 3 has been synthetized by a adapted sol-gel method and entraped in poly ε-caprolactone (PCL) nanocapsules. The superparamagnetic nanocapsules have been formulated by double emulsion evaporation method. Some variables affecting the polydispersity index, zeta potential surface and size of nanocapsules were studied aiming optimize the formulation process of maghemite-loaded PCL nanocapsules. The following parameters were selected: sonication time, PCL concentration in organic phase, PVA concentration in external aqueous phase and maghemite/PCL weight ratio. Under these experimental conditions, the resulting nanocapsules displayed a mean size of about 346 nm and a maghemite content of about 7.5 µg/mg of nanocapsules and superparamagnetic behaviour at room temperature.

show abstract

supporting

confidence: 85%

Superparamagnetic maghemite loaded poly (ε- caprolactone) nanocapsules : characterization and synthesis optimization

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The use of the highest current values produced the highest temperatures. Thus, the heating effect could be controlled by adjusting the value of the apparent current [28,81,82]. In addition, in the best cases, achieved using 600 A, the temperature of samples with concentrations equal to 10 and 20 mg/mL increased from 25 to 37.7 and 47.1°C, respectively.…”

Section: Synthesis Of Ugi Magnetic Compositementioning

confidence: 99%

“…In addition, they could be very useful in magnetic hyperthermia therapy [22][23][24][25]. Magnetic particles modified with biodegradable PLGA or PLA were firstly prepared in the beginning of the 1990s by chemical adsorption or molecular interactions between a reactive polymer end group and the surface of the particle [26][27][28][29][30]. On the other hand, the surface modification of magnetic particles by chemical linkage of polymers is less documented, even less by the use of Ugi four component condensation (UFCC).…”

mentioning

confidence: 99%

PLA-b-PEG/magnetite hyperthermic agent prepared by Ugi four component condensation

Icart¹,

Santos²,

Pereira³

et al. 2016

Express Polym. Lett.

View full text Add to dashboard Cite

“…1 The systemic toxicity together with adverse side effects resulting from typical treatments have led to the discovery of site-specific treatments with the help of nanotechnology, which reduce the negative effects on normal tissues. 2 Nanomedicine likely increases the specificity of cancer therapy with the help of the cancer cell-specific delivery of anticancer medicine via nanoparticles equipped with targeting moieties.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-<em>co</em>-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Wu¹,

Wang²,

Wang³

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

In the current study, we synthesized prostate cancer-targeting poly(lactide- co -glycolic acid) (PLGA) nanobubbles (NBs) modified using A10-3.2 aptamers targeted to prostate-specific membrane antigen (PSMA) and encapsulated paclitaxel (PTX). We also investigated their impact on ultrasound (US) imaging and therapy of prostate cancer. PTX-A10-3.2-PLGA NBs were developed using water-in-oil-in-water (water/oil/water) double emulsion and carbodiimide chemistry approaches. Fluorescence imaging together with flow cytometry verified that the PTX-A10-3.2-PLGA NBs were successfully fabricated and could specifically bond to PSMA-positive LNCaP cells. We speculated that, in vivo, the PTX-A10-3.2-PLGA NBs would travel for a long time, efficiently aim at prostate cancer cells, and sustainably release the loaded PTX due to the improved permeability together with the retention impact and US-triggered drug delivery. The results demonstrated that the combination of PTX-A10-3.2-PLGA NBs with low-frequency US achieved high drug release, a low 50% inhibition concentration, and significant cell apoptosis in vitro. For mouse prostate tumor xenografts, the use of PTX-A10-3.2-PLGA NBs along with low-frequency US achieved the highest tumor inhibition rate, prolonging the survival of tumor-bearing nude mice without obvious systemic toxicity. Moreover, LNCaP xenografts in mice were utilized to observe modifications in the parameters of PTX-A10-3.2-PLGA and PTX-PLGA NBs in the contrast mode and the allocation of fluorescence-labeled PTX-A10-3.2-PLGA and PTX-PLGA NBs in live small animals and laser confocal scanning microscopy fluorescence imaging. These results demonstrated that PTX-A10-3.2-PLGA NBs showed high gray-scale intensity and aggregation ability and showed a notable signal intensity in contrast mode as well as aggregation ability in fluorescence imaging. In conclusion, we successfully developed an A10-3.2 aptamer and loaded PTX-PLGA multifunctional theranostic agent for the purpose of obtaining US images of prostate cancer and providing low-frequency US-triggered therapy of prostate cancer that was likely to constitute a strategy for both prostate cancer imaging and chemotherapy.

show abstract

Superparamagnetic PLGA-iron oxide microcapsules for dual-modality US/MR imaging and high intensity focused US breast cancer ablation

Cited by 181 publications

References 33 publications

Superparamagnetic maghemite loaded poly (ε- caprolactone) nanocapsules : characterization and synthesis optimization

Superparamagnetic maghemite loaded poly (ε- caprolactone) nanocapsules : characterization and synthesis optimization

PLA-b-PEG/magnetite hyperthermic agent prepared by Ugi four component condensation

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-<em>co</em>-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

Contact Info

Product

Resources

About